StockMarketWire.com - Hardman & Co has issued a research report on Allergy Therapeutics.

It says: "Pollinex Quattro driving US market opportunity. AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. It has an underlying profitable and cash generative business despite its lead product being available only on a 'Named Patient' basis. However, protocols agreed with EU and US regulators are in place to get Pollinex Quattro approved as a biological.

"The US opportunity is enormous and only two players have short-course treatments. There is a valuation mis-match between AGY and its peers, which either have no growth or little marketing experience, which provides scope for considerable upside towards our risk-adjusted DCF valuation of 93p per share."


At 2:55pm: [LON:AGY] Allergy Therapeutics PLC share price was +0.25p at 28.5p



Story provided by StockMarketWire.com